Gocovri, a medication used to treat dyskinesia in Parkinson's disease patients, has a list price that can vary by dosage and quantity. Without insurance, the cost can be significant. For example, a 30-day supply of Gocovri 34.8 mg/24.3 mg extended-release capsules may cost several thousand dollars [1].
How can I get Gocovri at a lower price?
Individuals seeking to reduce the cost of Gocovri may be eligible for patient assistance programs or discount cards. Adagio Medical, the manufacturer of Gocovri, offers a Gocovri Savings Card. This card can help eligible patients save on their out-of-pocket costs, potentially reducing them to as low as $0 for a month's supply, with certain limits and conditions [2]. Information on eligibility and how to obtain these savings can typically be found on the manufacturer's official website [2].
What factors influence Gocovri pricing?
The price of Gocovri is influenced by several factors, including the prescribed dosage, the quantity dispensed, and the specific pharmacy where it is filled. Insurance coverage also plays a substantial role, with copayments varying widely depending on the patient's insurance plan. The list price, often referred to as the wholesale acquisition cost (WAC), represents the drug's cost before any discounts or insurance negotiations [1].
Are there Gocovri discount programs available?
Yes, Adagio Medical provides a Gocovri Savings Card program to make the medication more accessible. This program is designed to lower the out-of-pocket expenses for eligible patients [2]. The specifics of the savings, such as monthly maximums and eligibility criteria, are detailed by the manufacturer.
What is the list price for Gocovri?
The list price for Gocovri can be several thousand dollars for a one-month supply of certain dosages. For instance, a 30-day supply of Gocovri 34.8 mg/24.3 mg extended-release capsules has a significant out-of-pocket cost for those without insurance or discount programs [1].
What is Gocovri used for?
Gocovri (osmolex ER) is indicated for the treatment of dyskinesia in patients with Parkinson's disease who are on dopaminergic therapy. It is also approved for managing Parkinson's disease motor fluctuations [3].
Sources:
1. https://www.goodrx.com/gocovri
2. https://www.drugpatentwatch.com/gocovri-discount
3. https://www.drugpatentwatch.com/gocovri